Head-to-head evidence
AAV-hTERT vs GV1001
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Telomerase (hTERT) · full Alzheimer's Disease pipeline
AAV-hTERT
Developed by Libella Gene Therapeutics
NCT04133454 · Phase 1 · status unknown
All participants received the same single-dose treatment with no comparison group, randomization, or blinding, so the study cannot demonstrate a treatment effect. Results have not yet been posted.
GV1001
Developed by GemVax & KAEL
NCT05189210 · Phase 2 · completed
The study was randomized, quadruple-blind, and placebo-controlled, with 199 participants, and used a validated clinical cognitive endpoint. However, the primary comparison has no posted result, so it is not possible to determine whether GV1001 met its endpoint.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: January 2028 · NCT05303701 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AAV-hTERT's landscape · GV1001's landscape